Related Experiment Video
Updated: Sep 22, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.6K
Acetylated tau: A missing link between head injury and dementia
Zhen Zhao1, Berislav V Zlokovic1
1Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Med (New York, N.Y.)
|May 19, 2022
Summary
Head injury significantly increases Alzheimer's disease risk. Shin et al. identified a key molecular pathway connecting head trauma to Alzheimer's pathophysiology, offering potential new therapeutic targets.
Area of Science:
- Neuroscience
- Pathophysiology
- Molecular Biology
Background:
- Head injury is a major environmental risk factor for Alzheimer's disease (AD) and dementia.
- The underlying mechanisms linking traumatic brain injury (TBI) to AD remain poorly understood.
- Current therapeutic strategies for TBI-induced neurodegeneration are limited.
Purpose of the Study:
- To elucidate the molecular pathways mediating the link between head injury and Alzheimer's disease.
- To identify novel therapeutic targets for preventing or treating AD following head trauma.
- To advance the understanding of TBI's long-term neurological consequences.
Main Methods:
- Utilized a combination of molecular biology techniques and in vivo models.
- Investigated specific signaling cascades activated by head injury.
- Analyzed changes in protein expression and cellular function relevant to AD pathology.
Main Results:
- Discovered a novel molecular pathway directly linking head injury to key aspects of Alzheimer's disease pathology.
- Identified specific molecular mediators that are upregulated following head trauma.
- Demonstrated the potential of targeting this pathway to mitigate neurodegenerative changes.
Conclusions:
- Head injury initiates a cascade of molecular events that contribute to Alzheimer's disease development.
- The identified pathway represents a promising target for therapeutic intervention.
- Further research into this pathway could lead to effective treatments for TBI-related dementia.
Related Concept Videos
Alzheimer's Disease: Overview
692
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
692
Dementia
183
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
183
Alzheimer's Disease: Treatment
270
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
270

